Evaluate the Efficacy, Safety and Tolerability of Fecal Microbiota Transfer for the Treatment of Patients With Nonalcoholic Steatohepatitis

Exclusion Criteria

• •1. Evidence of other type of liver disease.
• •2. History of high alcohol intake (daily consumption \> 30 g/day for men and \> 20 g/day for women).
• •3. Weight change of more than 5% in the 3 months prior to screening.
• •4. Subjects with HbA1c\> 9.5%. For subjects with an HbA1c\> 9.5% at the screening visit, a repeat test may be performed within the screening window.
• •A repeated result of HbA1c\> 9.5% will result in exclusion.
• •5. Diabetic patients with:
• •* Insulin treatment.
• •* Changes in antidiabetic medication in the 4 months prior to liver biopsy according to the following conditions:
• •* Modification of the dose of treatment with glucagon agonists type 1 (GLP-1).
• •* Implementation of treatment with a new antidiabetic.
• •6. History of bariatric surgery.
• •7. Cirrhosis.
• •8. Portal thrombosis.
• •9. Known or suspected hepatocellular carcinoma.
• •10. Clinically significant gastrointestinal, cardiovascular, neurological, psychiatric, metabolic, renal, hepatic, respiratory, inflammatory or infectious disease, as determined by the investigator.
• •11. An estimated glomerular filtration rate (eGFR) \<45 ml / min / 1.73 m2 (calculated by the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] method).
• •12. Medical conditions that decrease life expectancy to less than 2 years, including cancer.
• •13. Presence of an inherited or acquired immunodeficiency.
• •14. Diagnosis of inflammatory bowel disease (Crohn's disease, ulcerative colitis, microscopic colitis), active irritable bowel syndrome (within the last 2 years according to Rome IV criteria), celiac disease not well controlled with a gluten-free diet, active gastroparesis, toxic megacolon.
• •15. Major intra-abdominal surgery in the 2 months prior to randomization of the patient in the study.
• •16. Antibiotic intake in the 8 weeks prior to the screening date.
• •17. Probiotic/prebiotic/marketed synbiotic intake in the 4 weeks prior to the screening date.
• •18. Pregnancy or lactation.
• •19. Any other condition that, in the opinion of the investigator, could prevent or hinder compliance.
• •20. Use of medication with potential steatogenic effect (corticosteroids, valproic acid, amiodarone and/or tamoxifen) within the 6 months prior to the first dose of study drug.